Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Thursday broker round-up

Thu, 04th Feb 2016 16:07

(ShareCast News) - Coca-Cola HBC: Barclays downgrades to underweight with a target of 1325p.TalkTalk: Goldman Sachs downgrades to neutral with a target of 271p.Paragon Group: JP Morgan downgrades to neutral and sets a 380p target.Antofagasta: Investec reiterates sell with a target of 305p.Angloamerican: Credit Suisse keeps at neutral with a 320p target.BHP Billition: Jefferies reiterates buy with a 800p target.Astrazeneca: UBS maintains buy, 5000p target.Johnson Matthey: JP Morgan and Exane BNP Paribas keep at neutral and Numis reiterates buy with a target price of 2995p.Londonmetric Property: HSBC keeps at hold with a target of 169p and JP Morgan maintains overweight, 190p target.Beazley: Numis and Shore Capital recommend buy and and UBS reiterates neutral, 376p target.Smith & Nephew: UBS keeps at buy with a 1250p target, Numis reiterates add with a 1242p target and Credit Suisse maintains neutral with a target of 1105p.Royal Bank of Scotland: HSBC keeps at hold, 260p target and Exane BNP Paribas reiterates outperform with a 370p target.Compass Group: Shore Capital and Panmure keep at hold, UBS keeps at neutral with a 1200p target and Numis reiterates buy with a 1150p target.

Related Shares

More News
Today 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for pr...

Today 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood canc...

29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negoti...

29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while a...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.